Chantal Rodgarkia-Dara

Chantal Rodgarkia-Dara

UNVERIFIED PROFILE

Are you Chantal Rodgarkia-Dara?   Register this Author

Register author
Chantal Rodgarkia-Dara

Chantal Rodgarkia-Dara

Publications by authors named "Chantal Rodgarkia-Dara"

Are you Chantal Rodgarkia-Dara?   Register this Author

8Publications

160Reads

30Profile Views

Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.

Anticancer Res 2009 Apr;29(4):1181-7

Department of Otorhinolaryngology, University Hospital Giessen and Marburg, Campus Marburg, Deutschhausstrasse 3, D-35037 Marburg, Germany.

View Article

Download full-text PDF

Source
April 2009

NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A.

Cancer Res 2009 Jan;69(1):235-42

Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-2144DOI Listing
January 2009

Activins and activin antagonists in hepatocellular carcinoma.

World J Gastroenterol 2008 Mar;14(11):1699-709

Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, Vienna A-1090, Austria.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695910PMC
http://dx.doi.org/10.3748/wjg.14.1699DOI Listing
March 2008

Oncogenic c-H-ras deregulates survivin expression: an improvement for survival.

FEBS Lett 2007 Oct 21;581(25):4921-6. Epub 2007 Sep 21.

Clinics of Internal Medicine I, Division Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.febslet.2007.09.023DOI Listing
October 2007

The activin axis in liver biology and disease.

Mutat Res 2006 Nov-Dec;613(2-3):123-37. Epub 2006 Sep 25.

Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mrrev.2006.07.002DOI Listing
January 2007

Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor.

FEBS Lett 2006 Sep 4;580(20):4793-800. Epub 2006 Aug 4.

Department of Otolaryngology, Head and Neck Surgery, Philipps University Marburg, Deutschhausstrasse 3, D-35037 Marburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.febslet.2006.07.064DOI Listing
September 2006